Helping precision medicine SCIEX to be at the forefront
Original Health Weekly 2018-12-06 22:59:34
In the report of the 19th National Congress of the Communist Party of China, General Secretary Xi Jinping proposed to promote the implementation of a healthy China strategy, and pointed out that “people’s health must be placed in a strategic position as a priority for development.” People’s health is now an important support for China’s entry into a harmonious society, and the research and development of life sciences is an integral part of helping people’s health.
From November 24th to 26th, 2018, the 2018 China Mass Spectrometry Academic Conference was held in Guangzhou Dongfang Hotel. Reports were made on multi-omics disease research and its diagnosis, clinical application and health management. Follow the Healthy China strategy, strengthen the field of life science research, and apply mass spectrometers to help precision medicine.
It is understood that SCIEX, which has been deeply involved in the field of liquid chromatography and mass spectrometry, has a history of more than 40 years of brilliant technological innovation. It is a world-renowned supplier of life science analytical instrument technology development and is committed to assisting in solving complex life science problems. SCIEX provides equipment, software, technology and other services for many fields of life sciences, including protein biomarker research, disease research, drug research and development, food safety and environmental testing. Are there any new advances in the multi-omics research and application of diseases?
Multi-omics research of disease helps provide more accurate result analysis
Multi-omics research has been a hot stage in recent years, and it is expanded based on the limitations of single-omics research. With the development of science and technology, a single omics can no longer meet the needs of scientific research. As a hot spot for promoting scientific research, multi-omics has received widespread attention, and disease research has also shown a trend of development of multi-omics. It not only promotes the research of disease mechanism and the determination of pathogenic targets, but also provides new ideas for basic disease science and precision medicine research.
Dr. Wenhai Jin, Director of Strategic Development for the Asia-Pacific Region of SCIEX, said that multi-omics research was originally related to systems biology and evolved on this basis. It includes genomics, proteomics, metabolomics, and lipidomics.
It mainly explores and solves the cause of the problem from the bottom cause level, and explores and solves the problem of how to treat the problem from the surface cause level. On this basis, the advantage is that medical staff can obtain more reliable diagnosis and treatment results and richer data through multi-omics integrated analysis.
He also said that for multi-omics disease research, it can be summarized as the following two advantages: 1. Exploring the pathogenic factors, from the bottom can understand why and how the disease occurs? 2. Through multi-omics joint analysis, it can help precision medicine and provide new ideas for disease research.
Mass spectrometer undertakes detection function for disease multi-omics research
What role does the mass spectrometer play in the multi-omics research of disease? Dr. Wenhai Jin pointed out that it is mainly responsible for disease-related “proteins” (proteomics) and “small molecule compounds” (metabolites). And lipidomics) detection and quantification functions. These proteins and small molecules are usually known biomarkers (defects in traditional detection methods) or potential biomarkers (need to be further verified and confirmed in a larger population), and targeted analysis by mass spectrometry can be used to target They carry out accurate detection and quantification, combined with genomics to explore the pathogenic mechanism of the disease, and then promote the early diagnosis and prevention of tumors. At present, there are countless potential biomarkers discovered by multi-omics, and the real clinical transformation and application depends largely on the targeted mass spectrometry detection technology.
4500MD mass spectrometer
Merely taking on the role of testing, it cannot be said that it can help precision medicine! He introduced that in biopharmaceuticals, liquid-phase mass spectrometry is used to provide analysis of its components for medicine. For example, drugs in Europe, the United States and other countries are not very suitable in China due to reasons such as price and patent protection. However, some biological drugs can be legally produced by other pharmaceutical companies to produce generic drugs after the patent expires; how to control imitations The properties of pharmaceuticals are infinitely close to the original research drugs, so they must rely on mass spectrometry. Mass spectrometry can help companies produce drugs with the same therapeutic efficacy with controllable side effects. At the same time, SCIEX and some hospitals are cooperating to carry out the work of testing the blood concentration of therapeutic drugs, and to achieve personalized drug delivery services for one person, one dose.
He believes that the ultimate goal of scientific and technological research is to benefit the people, promote the implementation of the healthy China strategy, and accelerate the transformation of clinical research results, which is also the work of SCIEX.
3200MD mass spectrometer
The future will be more intelligent and precise
“Intelligence and precision are an aspect that various industries are striving to transform now, and the development of mass spectrometers in the future will also move forward in this aspect. The advantage of intelligence and precision lies in the ability to combine the needs of medical scenarios and use deep learning and algorithms. The massive data is modularized, and the quantitative results can be calculated quickly to make the diagnosis of the disease more accurate, which can reduce the burden on clinicians and reduce misdiagnosis and missed diagnosis.” Jin Wenhai explained.
The development of science and technology will eventually be implemented on the ground. For the future development of the mass spectrometry industry in the field of medical and health? He responded that the future development cannot be separated from health. For example, it may be combined with imaging technology (such as ARVR), and it will also be combined with big data. To assist medical and health care, more convenient drugs and applications will emerge.
Guangdong Science and Technology News Yao Zanyuan